OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Daneshmand on Blue Light Cystoscopy for Bladder Cancer

May 26th 2017

Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.

Dr. Shain Discusses Emerging Agents in Multiple Myeloma

May 26th 2017

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors

May 26th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

Dr. Shah on Status of CAR T-cell Therapies in ALL

May 26th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Dr. Baz on Varying Treatment Approaches for Patients With Multiple Myeloma

May 26th 2017

Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Dr. Badani on the Benefits of Robotic Surgery for Kidney Cancer

May 25th 2017

Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.

Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

May 25th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Dr. Wingo on Advances of Surgical Technology in Gynecologic Cancers

May 25th 2017

Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the advances of surgical technology in gynecologic cancers.

Dr. Lallas on Challenges With Immunotherapy in Genitourinary Malignancies

May 25th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC

May 24th 2017

Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

The Development of Galectin-1 for Head and Neck Cancer

May 24th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.

Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

May 24th 2017

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Dr. Sears on Ongoing Research of Microbiota in CRC

May 24th 2017

Cynthia L. Sears, MD, professor of Medicine, at Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses ongoing research of microbiota for patients with colorectal cancer (CRC).

Dr. Sartor on Sipuleucel-T in mCRPC

May 24th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Moore on the Results of the NOVA Trial in Ovarian Cancer

May 23rd 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

Dr. Chase Discusses Risk Factors in Gynecologic Cancers

May 23rd 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the risk factors in gynecologic cancers.

Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma

May 23rd 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).

Dr. Parikh on the Significance of the CLL-IPI

May 23rd 2017

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).

Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies

May 23rd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses resistance to HER2-targeted therapy in breast cancer.

Dr. Matulonis on Toxicities With PARP Inhibitors in Ovarian Cancer

May 23rd 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.